News Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
0.642 ^USD	-2.04%		+3.57%	-52.44%

30/04	Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600	CI
04/04	Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600	30/04	AQ
Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600	30/04	CI
Biora Therapeutics : Form 8937 – Convertible Note Exchange (December 19, 2023)	11/04	PU
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology	08/04	AQ
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development	04/04	AQ
Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	04/04	CI
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	04/04	AQ
Athyrium Capital Management Engages in Discussions with Biora Therapeutics	03/04	CI
Top Midday Decliners	01/04	MT
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	01/04	AQ
Transcript : Biora Therapeutics, Inc., Q4 2023 Earnings Call, Mar 26, 2024	27/03
Biora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Biora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03	CI
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	27/03	AQ
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update	18/03	AQ
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset	11/03	AQ
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600	26/02	AQ
Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600	26/02	CI
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium	08/02	AQ
Transcript : Biora Therapeutics, Inc. - Special Call	29/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Summary

Filters